Conventional antiresorptive agents such as zoledronic acid, have also been reported to promote osteoclast ferroptosis in preclinical models
[DOI] [PubMed] [Google Scholar] 31.Hayek A, Culler FL, Beattie GM, Lopez AD, Cuevas P, Baird A
Why Employers Are Zeroing In On GLP-1s The numbers tell the story: 40% of US adults are living with obesity, with projections closer to 50% by 2030 Employers spend $6,472 more per year on employees with obesity than on healthy-weight employees across medical, productivity, disability, and workers comp Individuals who use GLP-1s can lose between 2.5% and 20% of their initial body weight when taking the medication as instructed Employers want to support prevention, not wait until employees are sicker to qualify for care
RTA GLP-3 20MG Next-Generation Peptide for Weight Management & Metabolic Optimization RTA GLP-3 20MG is a revolutionary multi-receptor agonist designed to support weight loss, metabolic health, and energy balance